Hence, CMB-PTX-CRISPR/Cas9 therapy may involve in the occurrence and progression of endometrial cancer via regulation of GSK-3, P21, P27, Bad, C-erbB-2, and mTOR expressions. Here, BAD is linked to endometrial cancer.